<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2218-3620</journal-id>
<journal-title><![CDATA[Revista Universidad y Sociedad]]></journal-title>
<abbrev-journal-title><![CDATA[Universidad y Sociedad]]></abbrev-journal-title>
<issn>2218-3620</issn>
<publisher>
<publisher-name><![CDATA[Editorial "Universo Sur"]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2218-36202022000600658</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Preparation of a powder for oral suspension of spironolactone: physicochemical and microbiological characterization]]></article-title>
<article-title xml:lang="es"><![CDATA[Preparación de un polvo para suspensión oral de espironolactona: caracterización fisicoquímica y microbiológica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mayes Cisneros]]></surname>
<given-names><![CDATA[Selvin Yassir]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Iraizoz]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ponce]]></surname>
<given-names><![CDATA[Henry Daniel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Enríquez de Madrid]]></surname>
<given-names><![CDATA[María de Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sosa]]></surname>
<given-names><![CDATA[Lilian Elisa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,National Autonomous University of Honduras (UNAH)  ]]></institution>
<addr-line><![CDATA[ Tegucigalpa]]></addr-line>
<country>Honduras</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,University of Habana  ]]></institution>
<addr-line><![CDATA[ Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>14</volume>
<numero>6</numero>
<fpage>658</fpage>
<lpage>669</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2218-36202022000600658&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2218-36202022000600658&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2218-36202022000600658&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT The objective of this study was to formulate three suspensions of powdered spironolactone for reconstitution (5 mg/mL) for pediatric use. Methodology. The tests were carried out: sedimentation time, pH, rheology, particle size, polydispersity, and Z potential of the three formulations (F1, F2, and F3) to choose the suspension with the best results. The chosen formulation underwent: accelerated physical stability, dissolution test, drug quantification, and microbiological stability stored at 4, 25, and 40°C (days 0, 15, and 30). Results. Of the three formulations, F2 and F3 remained suspended for more than 24 h, but not F1. The pH values were suitable for F1, F2, and F3. The particle sizes, polydispersity, and Z potential were ideal for F2 (chosen formulation). Spironolactone content remained within the stipulated parameters at temperatures of 4 and 25 °C, not at 40 °C. The dissolution test showed that the F2 released the drug faster than the Aldactone® tablet. Regarding the microbiological tests, the F2 remained stable for 30 days, with counts lower than 10 CFU/mL. Conclusion. F2 is a suitable formulation for use in pediatrics.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El objetivo de este estudio fue formular tres suspensiones de espironolactona en polvo para reconstitución (5 mg/mL) para uso pediátrico. Metodología. Se realizaron las pruebas: tiempo de sedimentación, pH, reología, tamaño de partícula, polidispersidad y potencial Z de las tres formulaciones (F1, F2 y F3) para elegir la suspensión con mejores resultados. La formulación elegida pasó por: estabilidad física acelerada, prueba de disolución, cuantificación de drogas y estabilidad microbiológica almacenada a 4, 25 y 40°C (días 0, 15 y 30). Resultados. De las tres formulaciones, F2 y F3 permanecieron suspendidas por más de 24 h, pero no F1. Los valores de pH fueron adecuados para F1, F2 y F3. Los tamaños de partícula, la polidispersidad y el potencial Z fueron ideales para F2 (formulación elegida). El contenido de espironolactona se mantuvo dentro de los parámetros estipulados a temperaturas de 4 y 25 °C, no a 40 °C. La prueba de disolución mostró que el F2 liberaba la droga más rápido que la tableta Aldactone®. En cuanto a las pruebas microbiológicas, la F2 se mantuvo estable durante 30 días, con recuentos inferiores a 10 UFC/mL. Conclusión. F2 es una formulación adecuada para su uso en pediatría.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[spironolactone]]></kwd>
<kwd lng="en"><![CDATA[suspension]]></kwd>
<kwd lng="en"><![CDATA[pediatric use]]></kwd>
<kwd lng="en"><![CDATA[Physicochemical stability]]></kwd>
<kwd lng="en"><![CDATA[microbiological stability]]></kwd>
<kwd lng="es"><![CDATA[espironolactona]]></kwd>
<kwd lng="es"><![CDATA[suspensión]]></kwd>
<kwd lng="es"><![CDATA[uso pediátrico]]></kwd>
<kwd lng="es"><![CDATA[estabilidad fisicoquímica]]></kwd>
<kwd lng="es"><![CDATA[estabilidad microbiológica]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvarado]]></surname>
<given-names><![CDATA[M. Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Daniel Ponce]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Enríquez]]></surname>
<given-names><![CDATA[M. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Sosa]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización fisicoquímica y microbiológica de suspensiones de albendazol para uso pediátrico]]></article-title>
<source><![CDATA[Universidad Y Sociedad]]></source>
<year>2021</year>
<volume>13</volume>
<numero>^sS3</numero>
<issue>^sS3</issue>
<supplement>S3</supplement>
<page-range>515-23</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batchelor]]></surname>
<given-names><![CDATA[H.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Marriott]]></surname>
<given-names><![CDATA[J.F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulations for children: problems and solutions]]></article-title>
<source><![CDATA[British Journal of Clinical Pharmacology]]></source>
<year>2015</year>
<volume>79</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>405-18</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bashan]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[de-Bashan]]></surname>
<given-names><![CDATA[L.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Prabhu]]></surname>
<given-names><![CDATA[S.R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in plant growth-promoting bacterial inoculant technology: formulations and practical perspectives (1998-2013)]]></article-title>
<source><![CDATA[Plant Soil]]></source>
<year>2014</year>
<volume>378</volume>
<page-range>1-33</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Durrant]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The responsibility of the pharmaceutical industry]]></article-title>
<source><![CDATA[Clinical Microbiology, and Infection]]></source>
<year>2001</year>
<volume>7</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2-4</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elmowafy]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ibrahim]]></surname>
<given-names><![CDATA[H.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[M.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Shalaby]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Salama]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Hefesha]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atorvastatin-loaded nanostructured lipid carriers (NLCs): Strategy to overcome oral delivery drawbacks]]></article-title>
<source><![CDATA[Drug Delivery]]></source>
<year>2017</year>
<page-range>24-932-41</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ervasti]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Niinikoski]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Mäki-Lohiluoma]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Leppinen]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Ketolainen]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Korhonen]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Lakio]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Comparison of Two Challenging Low-Dose APIs in a Continuous Direct Compression Process.]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2020</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>279</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernandez]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Tejada]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Arteta]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[J.T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2011</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>53-72</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Le Bolay]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Frances]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheological behavior and related granulometric properties of dense aggregated suspensions during an ultrafine comminution process]]></article-title>
<source><![CDATA[Powder Technology]]></source>
<year>2003</year>
<volume>130</volume>
<numero>1-3</numero>
<issue>1-3</issue>
<page-range>407-14</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[P.Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preformulation studies of spironolactone: Effect of pH, two buffer species, ionic strength, and temperature on stability]]></article-title>
<source><![CDATA[American pharmacist association]]></source>
<year>1991</year>
<volume>80</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>551-3</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Provenza]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<source><![CDATA[Caracterización y estudio de estabilidad de fórmulas magistrales líquidas de administración oral]]></source>
<year>2014</year>
<publisher-name><![CDATA[Universidad de Barcelona]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Provenza]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Calpena]]></surname>
<given-names><![CDATA[A.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Mallandrich]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ruíz]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Clares]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development, Physical-Chemical Stability, and Release Studies of Four Alcohol-Free Spironolactone Suspensions for Use in Pediatrics.]]></article-title>
<source><![CDATA[Dissolution Techonolgies]]></source>
<year>2014</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-30</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Provenza]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Calpena]]></surname>
<given-names><![CDATA[A.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Mallandrich]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Halbaut]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Clares]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Design and physicochemical stability studies of pediatric oral formulations of sildenafil]]></article-title>
<source><![CDATA[International Journal of Pharmaceutics]]></source>
<year>2014</year>
<volume>460</volume>
<page-range>234-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="">
<collab>National Center for Biotechnology Information</collab>
<source><![CDATA[PubChem Compound Summary for CID 5833, Spironolactone]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salgado]]></surname>
<given-names><![CDATA[A.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Rosa]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of spironolactone in an extemporaneously prepared aqueous suspension: the importance of microbiological quality of compounded pediatric formulation]]></article-title>
<source><![CDATA[European Journal Hospitality Pharmacy Science]]></source>
<year>2005</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>68-73</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shamma]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Elkasabgy]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Design freeze-dried Soluplus/polyvinyl alcohol-based film for the oral delivery of an insoluble drug for pediatric use]]></article-title>
<source><![CDATA[Drug Delivery]]></source>
<year>2016</year>
<volume>23</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>489-99</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sosa]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Clares]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarado]]></surname>
<given-names><![CDATA[H.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Bozal]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Domenech]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Calpena]]></surname>
<given-names><![CDATA[A.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amphotericin B releasing topical nanoemulsion for the treatment of candidiasis and aspergillosis]]></article-title>
<source><![CDATA[Nanomedicine: Nanotechnology, Biology and Medicine]]></source>
<year>2017</year>
<volume>13</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2303-12</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thabet]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Klingmann]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Breitkreutz]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics]]></article-title>
<source><![CDATA[Journal Clinical of Pharmacology]]></source>
<year>2018</year>
<volume>58</volume>
<numero>10^sS26-S35</numero>
<issue>10^sS26-S35</issue>
<supplement>S26-S35</supplement>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="">
<collab>USP Ed. 35.</collab>
<source><![CDATA[Farmacopea de los Estados Unidos USP 35 NF 30]]></source>
<year>2012</year>
<volume>Vol. 1</volume>
<publisher-loc><![CDATA[Estados Unidos ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[R. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Cumming]]></surname>
<given-names><![CDATA[G. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Response of the Infant Kidney to Diuretic Drugs]]></article-title>
<source><![CDATA[Canadian Medical Association Journal]]></source>
<year>1964</year>
<volume>91</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>1149-53</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
